Syros Pharmaceuticals (SYRS) 10-K2023 FY Annual report

Filed: 27 Mar 24, 6:49am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: advocacy, aforementioned, archived, Article, AstraZeneca, attorney, auction, authentication, awaiting, bind, binding, blast, Boehringer, bolster, border, Bridge, Bristol, built, Canadian, Chamber, chose, closure, Commerce, content, corroborated, cut, cyber, cyclin, Dakota, destined, dispute, disputed, East, email, engineering, enjoined, ethical, extrapolate, filtered, fulfilled, guideline, hacking, Harmonisation, inevitable, Ingelheim, issuable, lesion, MAs, Merck, methodological, middle, missing, mobile, moratorium, navigate, Nevada, NIST, Nordisk, Novo, oIn, onsite, organizational, outplacement, pack, password, pattern, pave, PAYGO, phishing, PhRMA, provisionally, pulse, realignment, regression, Rescue, residual, restructuring, running, saturating, secondary, sequester, sequestration, speak, strongly, successor, sue, Taiho, traffic, transposed, truthful, unbiased, uncompensated, unscheduled, unsold, vendor, Washington, web, Windsor, Wisconsin

Removed: accelerate, acceleration, accumulate, addressable, aim, antitrust, arrest, ASH, back, baseline, bioavailable, blocking, BRAF, buy, caption, Carrick, category, CDK, Chinese, CLIA, collaborating, colorectal, complicating, conforming, contemplate, continually, converted, cure, customary, daily, deacetylation, death, delivered, diarrhea, digit, discovering, distributed, DOJ, DSMB, enrich, entirety, Eric, eudract, excipient, exercising, exert, fatigue, feature, field, formula, France, functional, generically, genetic, genome, Germany, Gilead, histology, histone, hospital, immune, immunological, implicated, induced, inhibited, inhibiting, inhibition, inseverable, intermittent, isotopically, Italy, judge, killing, labeled, leased, LRF, lung, lyophilization, metastatic, minimally, modulate, monocytic, moved, Myc, myelomonocytic, myeloproliferative, Nancy, nausea, NIH, nominated, nucleosome, NuRD, objective, observing, offshore, Olson, opt, ORR, ovarian, overproduced, PCT, PDX, Pharma, pharmaceutically, pharmacodynamic, phenotype, PK, plasma, PML, Potently, practitioner, preempted, preferential, preferentially, principally, pro, promoting, protective, Qurient, radiopharmaceutical, rarely, rata, Rb, reassessment, red, refund, reimbursable, reinvestment, relocation, remodeling, repatriated, repeated, researching, resistance, resource, ruled, salary, salt, silenced, Simonian, simplify, sixty, solution, standalone, steady, stereoisomer, structural, Subtopic, supplied, survive, therapeutically, thirty, thrive, tiered, tolerability, translational, transplant, Trisenox, turning, uncontrolled, uncured, unexpended, unilateral, unilaterally, Virtual, vomiting, Yungjin

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SYRS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT

TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Syros Pharmaceuticals, Inc. (the “Company”) for the fiscal year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Conley Chee, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: March 27, 2024		/s/ Conley Chee
		Conley Chee
		President and Chief Executive Officer (Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.